Table 1.
Summary of Evidence on Concurrent Chemoradiotherapy
| Author and Year | Clinical Stages | Interventions | Follow-Up | Outcomes |
|---|---|---|---|---|
| Biswas 201919 | III IV |
Arm 1 (n=20): Age <40 Y, CCRT (cisplatin + RT 70 Gy) Arm 2 (n=26): Age >40 Y, CCRT (cisplatin + RT 70 Gy |
11.1 M | OR: Arm 1, 63.5%; Arm 2, 65.9% |
| Chhatui 201521 | III IV |
(n=25): CCRT (cisplatin + RT 70 Gy) | 15 M | DFS: 69% CR: 52% |
| Elbers 201724 | III IV |
(n=100): CCRT (cisplatin + RT up to 70 Gy) | 13 M | OS [5 Y]: 22% LRC [5 Y]: 49% DFS [5 Y]: 22% DSS [5 Y]: 39% |
| Foster 201825 | III IV |
(n=140): CCRT (CT + RT up to 75 Gy) | 5.7 Y | OS [5 Y]: 63.2% LRC [5 Y]: 78.6% PFS [5 Y]: 58.7% DC [5 Y]: 87.2% |
| Hayashi 201926 | III IV |
(n=46): CCRT (docetaxel + cisplatin + RT up to 60 Gy) | 40 M | OS [3Y]: 64.3% LRC [3Y]: 84.3% |
| Hino 201127 | II III IV |
(n=16): CCRT (S-1+ RT 30 Gy) | 7.4 M | OR: 87.5% OS [Median]: 42.5 M PFS [Median]: 6.3 M |
| Iqbal 201528 | III IV |
(n=63): CCRT (gemcitabine + cisplatin + RT 55 Gy) | 60 M | OS [5 Y]: 30% PFS [5 Y]: 49% DFS [5 Y]: 30% |
| Murakami 201732 | III IV |
(n=47): CCRT (S-1+ RT up to 70 Gy) | 22 M | OS [3 Y]: 37% PFS [3 Y]: 27% |
| Oyama 202033 | III IV |
(n=37): CCRT (docetaxel + nedaplatin + RT up to 70 Gy) |
40 M | OS [5 Y]: 64.5% DF [5 Y]: 59.9% LC [5 Y]: 85.5% |
| Pederson 201135 | III IV |
(n=20): CCRT (5-FU + hydroxyurea + RT up to 75 Gy) | 60 M | OS [2 Y]: 76% OS [5 Y]: 76% DFS [2 Y]: 71% DFS [5 Y]: 71% LRC [2 Y]: 90% LRC [5 Y]: 90% |
| Sato 201940 | III IV |
(n=17): CCRT (docetaxel+ cisplatin + RT up to 66 Gy) | 41 M | OS [3 Y]: 52.9% OS [5 Y]: 33.0% LRC [3 Y]: 50.9% LRC [5 Y]: 50.9% |
| Scher 201541 | I II III IV |
(n=73): CCRT (cisplatin + carboplatin + 5-FU or paclitaxel + RT up to 70 Gy) | 73.1 M | OS [5 Y]: 15% LRC [5 Y]: 37.4% DC [5 Y]: 70.2% |
| Shia 202042 | III IV |
Arm 1 (n=256): CCRT Arm 2 (n=227): Non-treatment |
15 M | Death risk: Arm 1, 1 (Ref); Arm 2, 1.60 (1.30–1.97) |
| Zhang 201350 | III IV |
(n=10): CCRT (cisplatin or carboplatin + RT up to 70Gy) | 3.52 Y | OS [2 Y]: 20% OS [5 Y]: 10% DSS [2 Y]: 26% DSS [5 Y]: 13% DFS [2 Y]: 13% |
Abbreviations: CCRT, concurrent chemoradiotherapy; CR, complete response; CT, chemotherapy; DC, distant control; DF, disease free rate; DFS, disease-free survival; DSS, disease specific survival; FU, fluorouracil; LC, local control; LRC, locoregional control; M, months; OR, overall response, OS, overall survival; PFS, progression-free survival; RT, radiotherapy; Y, years.